BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026

BioAge Labs, Inc.

Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.
Preclinical DME model: oral BGE-102 achieved near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity.
BGE-102 ongoing Phase 1 shows favorable tolerability and robust reductions in hsCRP, IL-6, and IL-1β.
Additional milestones: 1H2026 complete Phase 1, start CV risk Phase 2a; 2H2026 CV risk data.
Cites growing clinical evidence for targeting inflammation in retinal diseases, including intravitreal IL-6 inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.